论文部分内容阅读
细胞色素Ｐ４５０ ２Ｃ１９（ＣＹＰ２Ｃ１９）又称为Ｓ－美芬妥英羟化酶，它的两个突变型等位基因ＣＹＰ２Ｃ１９ｍｌ和ＣＹＰ２Ｃ１９ｍ２是引起ＣＹＰ２Ｃ１９酶活性缺陷的原因．运用等位基因特异扩增法（ＡＳＡ）对肺癌患者、膀胱癌患者及正常人进行了ＣＹＰ２Ｃ１９基因分型研究，以探索ＣＹＰ２Ｃ１９酶活性与肺癌、膀胱癌易患性的关系．经过对７４例肺癌患者、５０例膀胱癌患者和７０例对照组的测定，发现肺癌组慢代谢的发生率为３２．４％，膀胱癌患者的慢代谢发生率为４．０％，而对照组中该值为 １５．７％，经ｘ~２统计有显著性差异；实验表明，ＣＹＰ２Ｃ１９酶活性的降低增加了肺癌发生的可能性，却降低了患膀胱癌的危险性．结果显示，ＣＹＰ２Ｃ１９参与了肺癌致癌物的清除和膀胱癌致癌物的激活，提示ＣＹＰ２Ｃ１９是一种肿瘤相关基因．
Cytochrome P450 2C19 (CYP2C19) is also known as S-Merantidol hydroxylase, and its two mutant alleles, CYP2C19ml and CYP2C19m2, are the causes of defects in CYP2C19 enzyme activity. Allele-specific amplification (ASA) was used to study the CYP2C19 genotyping of lung cancer patients, bladder cancer patients and normal individuals to explore the relationship between CYP2C19 enzyme activity and susceptibility to lung cancer and bladder cancer. After measuring 74 patients with lung cancer, 50 patients with bladder cancer and 70 controls, the incidence of slow metabolism was 32.4% in the lung cancer group and 4.0% in the bladder cancer patients. The value in the group was 15.7%. There was a statistically significant difference from the x~2 statistic. Experiments showed that the decrease of CYP2C19 enzyme activity increased the possibility of lung cancer but decreased the risk of bladder cancer. The results showed that CYP2C19 was involved in the removal of lung cancer carcinogens and the activation of bladder cancer carcinogens, suggesting that CYP2C19 is a tumor-associated gene.